Kyowa Awaits EU Decision On Drug For Treating Parkinson’s ‘Off’ Time
Cancer Prevention Pharma Wants A Re-Examination Of Negative Opinion On Flynpovi
Executive Summary
The European Medicines Agency is meeting this week to decide whether two new drugs, including one that enhances anti-parkinsonian activity, should be approved for use in the EU. Also, the sponsor of a treatment for the rare degenerative muscle disorder, Pompe disease, is expected to attend an oral explanation meeting to address last-minute questions.